Cancer has been a major killer disease across the globe and scientists have not yet determined a permanent cure for the problem. Various companies have made progress in identifying the best cure for the problem, and one of them is Seattle Genetics. The firm was founded by Clay Siegal who is an experience genetics and biotechnology expert. He has been heading the company for about two decades now and has transformed it into a leading medical research hub that has several professionals who are devoted to developing the best cure for cancer. Seattle Genetics offers excellent equipment that is used by the scientists in conducting their research.
Clay Siegall is highly knowledgeable in therapeutic drugs that are used in curing cancer. He is very determined to find a cure for the deadly disease, and this has motivated him to keep researching at Seattle Genetics. Siegall is an alumnus of the Maryland Zoology University, and he attended the University of George Washington for his Ph.D. Before establishing Seattle Genetics, Clay worked for a government body that is known as the National Cancer Institute. The Bristol-Meyers Squibb Pharmaceutical Research Institute also employed him to serve as a senior researcher.
Seattle Genetics’ progress in cancer research has been significant since it was established in 1998. The company as invented various technologies that are utilized in the manufacture of drugs that are used in the treatment of cancer patients. The primary creation of Seattle Genetics is antibody-drug conjugates (ADCs). The ADCs work efficiently by destroying all the cancer cells that grow in the patients. Another invention of the company is the brentuximab vedotin product.
The ADC formula that was developed by Seattle Genetics has currently been used by the firm and its partners in developing more than 21 different drugs. The company has acquired licenses that allow it to distribute its products across the globe. It has currently partnered with Takeda Pharmaceutical Company, which is a leading multinational pharmaceuticals corporation. ADCs are popular in the treatment of cancer since they are less destructive compared to various treatments that are currently being used. Clay Siegall has been appointed to serve on the boards of companies such as Alder Biopharmaceuticals and American Biomedical Association.